MPW
KTTA icon

Magnolia Private Wealth’s Pasithea Therapeutics KTTA Stock Holding History

Magnolia Private Wealth’s Portfolio KTTA Stock Details KTTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-33,333
Closed -$43K – 142
2025
Q4 		$43K Buy
+33,333
New +$29.3K 0.03% 120

Other funds holding KTTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $268M AUM 158.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Magnolia Private Wealth's KTTA Position: Q1 2026 in Review

Magnolia Private Wealth sold out of Pasithea Therapeutics (KTTA) in Q1 2026, closing a stake of 33,333 shares — an estimated $43K sold.

Magnolia Private Wealth first reported a position in KTTA in Q4 2025 and held it in 1 quarter. The position peaked at $43K in Q4 2025. 21 funds tracked by Wall St. Rank hold KTTA as of Q1 2026.

  • Magnolia Private Wealth reported no remaining Pasithea Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Magnolia Private Wealth sold 33,333 Pasithea Therapeutics shares in Q1 2026, an estimated $43K.
  • Magnolia Private Wealth first reported a position in Pasithea Therapeutics in Q4 2025 and held it in 1 quarter.
  • Magnolia Private Wealth's Pasithea Therapeutics position peaked at $43K in Q4 2025.
  • 21 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q1 2026.

Based on Magnolia Private Wealth's 13F filing for Q1 2026, filed 21 Apr 2026.